Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure

N. A. Awan, M. K. Evenson, K. E. Needham, T. O. Evans, J. Hermanovich, C. R. Taylor, Ezra A Amsterdam, D. T. Mason

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The achievement of satisfactory ambulatory therapy of severe chronic congestive heart failure may be helped by the development of safe and orally effective cardiotonic agents. Therefore, we evaluated by cardiac catheterization and limb plethysmography the temporal cardiocirculatory responses of the new ingestible β agonist pirbuterol in 10 coronary heart disease patients with severe congestive heart failure refractory to digitalis and diuretics. After a single oral dose of 0.4 mg/kg, ventricular dysfunction was considerably improved during 6 hours of hemodynamic monitoring. Cardiac index increased from a control of 1.7 l/min/m 2 to 2.6 l/min/m 2 (p<0.001) at 1 hour and to 2.4 l/min/m 2 (p<0.005) at 3 hours and was 2.2 l/min/m 2 (p<0.001) at 6 hours; left ventricular filling pressure decreased from a control of 24 mm Hg to 19 mm Hg (p<0.005) at 1 hour and to 18 mm Hg (p<0.005) at 3 hours and was 22 mm Hg (p<0.05) at 6 hours. Concomitantly, the peak increment in heart rate (6 beats/min) was minimal and without ectopy and mean arterial blood pressure decreased only 10 mm Hg. Total systemic vascular resistance declined by 887 dyn-sec-cm -5, forearm venodilation occurred and the rate-pressure product was unaltered. Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalCirculation
Volume63
Issue number1
StatePublished - 1981

Fingerprint

Heart Failure
Hemodynamics
Arterial Pressure
Cardiotonic Agents
Ventricular Dysfunction
Plethysmography
Digitalis
Left Ventricular Dysfunction
Ventricular Pressure
Cardiac Catheterization
Diuretics
Forearm
Vascular Resistance
Coronary Disease
Extremities
Heart Rate
Pressure
pirbuterol
Therapeutics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Awan, N. A., Evenson, M. K., Needham, K. E., Evans, T. O., Hermanovich, J., Taylor, C. R., ... Mason, D. T. (1981). Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. Circulation, 63(1), 96-101.

Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. / Awan, N. A.; Evenson, M. K.; Needham, K. E.; Evans, T. O.; Hermanovich, J.; Taylor, C. R.; Amsterdam, Ezra A; Mason, D. T.

In: Circulation, Vol. 63, No. 1, 1981, p. 96-101.

Research output: Contribution to journalArticle

Awan, NA, Evenson, MK, Needham, KE, Evans, TO, Hermanovich, J, Taylor, CR, Amsterdam, EA & Mason, DT 1981, 'Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure', Circulation, vol. 63, no. 1, pp. 96-101.
Awan NA, Evenson MK, Needham KE, Evans TO, Hermanovich J, Taylor CR et al. Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. Circulation. 1981;63(1):96-101.
Awan, N. A. ; Evenson, M. K. ; Needham, K. E. ; Evans, T. O. ; Hermanovich, J. ; Taylor, C. R. ; Amsterdam, Ezra A ; Mason, D. T. / Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. In: Circulation. 1981 ; Vol. 63, No. 1. pp. 96-101.
@article{37862d78b8324afa848e1fcb7f5ed183,
title = "Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure",
abstract = "The achievement of satisfactory ambulatory therapy of severe chronic congestive heart failure may be helped by the development of safe and orally effective cardiotonic agents. Therefore, we evaluated by cardiac catheterization and limb plethysmography the temporal cardiocirculatory responses of the new ingestible β agonist pirbuterol in 10 coronary heart disease patients with severe congestive heart failure refractory to digitalis and diuretics. After a single oral dose of 0.4 mg/kg, ventricular dysfunction was considerably improved during 6 hours of hemodynamic monitoring. Cardiac index increased from a control of 1.7 l/min/m 2 to 2.6 l/min/m 2 (p<0.001) at 1 hour and to 2.4 l/min/m 2 (p<0.005) at 3 hours and was 2.2 l/min/m 2 (p<0.001) at 6 hours; left ventricular filling pressure decreased from a control of 24 mm Hg to 19 mm Hg (p<0.005) at 1 hour and to 18 mm Hg (p<0.005) at 3 hours and was 22 mm Hg (p<0.05) at 6 hours. Concomitantly, the peak increment in heart rate (6 beats/min) was minimal and without ectopy and mean arterial blood pressure decreased only 10 mm Hg. Total systemic vascular resistance declined by 887 dyn-sec-cm -5, forearm venodilation occurred and the rate-pressure product was unaltered. Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure.",
author = "Awan, {N. A.} and Evenson, {M. K.} and Needham, {K. E.} and Evans, {T. O.} and J. Hermanovich and Taylor, {C. R.} and Amsterdam, {Ezra A} and Mason, {D. T.}",
year = "1981",
language = "English (US)",
volume = "63",
pages = "96--101",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure

AU - Awan, N. A.

AU - Evenson, M. K.

AU - Needham, K. E.

AU - Evans, T. O.

AU - Hermanovich, J.

AU - Taylor, C. R.

AU - Amsterdam, Ezra A

AU - Mason, D. T.

PY - 1981

Y1 - 1981

N2 - The achievement of satisfactory ambulatory therapy of severe chronic congestive heart failure may be helped by the development of safe and orally effective cardiotonic agents. Therefore, we evaluated by cardiac catheterization and limb plethysmography the temporal cardiocirculatory responses of the new ingestible β agonist pirbuterol in 10 coronary heart disease patients with severe congestive heart failure refractory to digitalis and diuretics. After a single oral dose of 0.4 mg/kg, ventricular dysfunction was considerably improved during 6 hours of hemodynamic monitoring. Cardiac index increased from a control of 1.7 l/min/m 2 to 2.6 l/min/m 2 (p<0.001) at 1 hour and to 2.4 l/min/m 2 (p<0.005) at 3 hours and was 2.2 l/min/m 2 (p<0.001) at 6 hours; left ventricular filling pressure decreased from a control of 24 mm Hg to 19 mm Hg (p<0.005) at 1 hour and to 18 mm Hg (p<0.005) at 3 hours and was 22 mm Hg (p<0.05) at 6 hours. Concomitantly, the peak increment in heart rate (6 beats/min) was minimal and without ectopy and mean arterial blood pressure decreased only 10 mm Hg. Total systemic vascular resistance declined by 887 dyn-sec-cm -5, forearm venodilation occurred and the rate-pressure product was unaltered. Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure.

AB - The achievement of satisfactory ambulatory therapy of severe chronic congestive heart failure may be helped by the development of safe and orally effective cardiotonic agents. Therefore, we evaluated by cardiac catheterization and limb plethysmography the temporal cardiocirculatory responses of the new ingestible β agonist pirbuterol in 10 coronary heart disease patients with severe congestive heart failure refractory to digitalis and diuretics. After a single oral dose of 0.4 mg/kg, ventricular dysfunction was considerably improved during 6 hours of hemodynamic monitoring. Cardiac index increased from a control of 1.7 l/min/m 2 to 2.6 l/min/m 2 (p<0.001) at 1 hour and to 2.4 l/min/m 2 (p<0.005) at 3 hours and was 2.2 l/min/m 2 (p<0.001) at 6 hours; left ventricular filling pressure decreased from a control of 24 mm Hg to 19 mm Hg (p<0.005) at 1 hour and to 18 mm Hg (p<0.005) at 3 hours and was 22 mm Hg (p<0.05) at 6 hours. Concomitantly, the peak increment in heart rate (6 beats/min) was minimal and without ectopy and mean arterial blood pressure decreased only 10 mm Hg. Total systemic vascular resistance declined by 887 dyn-sec-cm -5, forearm venodilation occurred and the rate-pressure product was unaltered. Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0019365102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019365102&partnerID=8YFLogxK

M3 - Article

C2 - 7438412

AN - SCOPUS:0019365102

VL - 63

SP - 96

EP - 101

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 1

ER -